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A B S T R A C T
Purpose
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. Monitoring minimal
residual disease (MRD) by using real-time quantitative polymerase chain reaction (RQ-PCR)
provides information for patient stratification and individual risk-directed treatment. Cooperative
studies have documented that measurement of blast clearance from the bone marrow during and
after induction therapy identifies patient populations with different risk of relapse. We explored the
possible contribution of measurements of MRD during the course of treatment.
Patients and Methods
We used RQ-PCR to detect MRD in 110 unselected patients treated in Italy in the International
Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leuke-
mia (AIEOP-BFM ALL 2000). The trial took place in AIEOP centers during postinduction
chemotherapy. Results were categorized as negative, low positive (below the quantitative range
[ 5 104]), or high positive ( 5 104). Patients with at least one low-positive or high-positive
result were assigned to the corresponding subgroup.
Results
Patients who tested high positive, low positive, or negative had significantly different cumulative
incidences of leukemia relapse: 83.3%, 34.8%, and 8.6%, respectively (P  .001). Two thirds of
positive cases were identified within 4 months after induction-consolidation therapy, suggesting
that this time frame may be most suitable for cost-effective MRD monitoring, particularly in
patients who did not clear their disease at the end of consolidation.
Conclusion
These findings provide further insights into the dynamic of MRD and the ongoing effort to define
molecular relapse in childhood ALL.
J Clin Oncol 32:3553-3558. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most
common type of cancer in children and adoles-
cents. With current risk-directed treatment
approaches, cure rates exceed 80%.1 Leukemia
relapse remains the most common cause of treat-
ment failure. Although a proportion of patients
may be rescued after relapse, second-line therapy
may be ineffective in most of the cases, despite
intensive approaches, including allogeneic hema-
topoietic stem-cell transplantation (HSCT).2,3
Minimal residual disease (MRD) monitoring is
currently considered the most reliable strategy to
evaluate early treatment response and to refine
stratification accordingly.4-9 Both highly sensitive
molecular polymerase chain reaction (PCR) and
multiparameter flow cytometry approaches may
be used to this purpose in the context of first-line,
relapse, or allogeneic HSCT trials.10-17 The use of
immune gene rearrangements by real-time quan-
titative PCR (RQ-PCR) allows stratification of
approximately 90% of the patients with a single
sensitive marker.17
These techniques allow identification of in-
sufficient blast cell clearance during initial treat-
ment with disease persistence and also allow
identification of the re-emergence of leukemic
cells, thus challenging the criteria for the defini-
tion of remission18,19 ormedullary relapse,which, at
this point, are based on standard morphologic evi-
dence of 25% leukemic blasts in the bone marrow
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(BM) in a patient who previously achieved morphologic complete
remission (CR).
Despite adequate technologies that arenowwidely available, only
a few studies have addressed the issue of predicting ALL relapse by
prospective, postinduction MRD monitoring. Conversion to MRD
positivity during early postconsolidation treatment in adult patients
with standard-risk ALL (SR-ALL) was strongly predictive of subse-
quent morphologic relapse.20 Although no interventional strategies
have been applied so far inALL, the experience of theGruppo Italiano
Malattie Ematologiche Maligne dell’Adulto in patients with acute
promyelocytic leukemia for which the administration of salvage ther-
apy at the time of molecular relapse improved the chance of rescuing
patients21 might suggest a potential benefit.
In this study, we addressed this issue by monitoring MRD
throughout the treatment program in children with ALL treated with
a Berlin-Frankfurt-Mu¨nster (BFM) –type intensive chemotherapy.
PATIENTS AND METHODS
Patients in this study were newly diagnosed with childhood ALL between
September 2000 and July 2006 and were enrolled onto the International
Collaborative Treatment Protocol for Children and Adolescents With Acute
Lymphoblastic Leukemia (AIEOP-BFM ALL 2000).6,10 AIEOP-BFM ALL
2000 trial patients from two AIEOP centers were eligible for our study.
Patient Stratification
The definitions for MRD risk are as follows: SR-MRD: MRDwas nega-
tive at day 33 (time point 1 [TP1]) and day 78 (TP2) by using at least two
molecular targets with a sensitivity  1  104; intermediate-risk MRD
(IR-MRD): MRD was positive at less than 5 104 at TP2; high-risk MRD
(HR-MRD): MRD was 5 104 at TP2. Patients with either prednisone-
poor response ( 1,000 circulating blasts per microliter on day 8) or patients
who did not achieve CR after induction phase IA or who had translocation
t(4;11) were all allocated to the HR group, independently of MRD results.
Treatment Protocol
Treatment was administered as reported elsewhere.6,10 Briefly, all pa-
tients were given a 7-day steroid prephase, induction protocols IA and IB,
followed by consolidation with high-dose methotrexate for non–high-risk
patients or block therapy for high-risk patients, then by reinduction and by
maintenance until 24 months from diagnosis. Treatment details, including
randomizations, are provided in the Appendix (online only).
BM Sampling
All patients underwent surveillance BM aspirate at the beginning of
protocol IB, protocol M or first block, protocol II or III, and continua-
tion therapy.
Patients in our study underwent additional surveillance aspirates ap-
proximately every 2 months during continuation therapy until month 24
from diagnosis and 2 months after treatment discontinuation. Material from
each TP was used for MRD determination. Collected samples were batched
and analyzed later on; treating physicians were blinded to the results.
Institutional review board approval for this trial was obtained locally by
each participating institution. Informed consent for MRD evaluation on any
BM aspirate was obtained from the parents or legal guardians.
Study Population
In all, 276 Philadelphia chromosome–negative patients were enrolled
onto the AIEOP-BFM ALL 2000 trial in two centers that adopted the addi-
tional MRD surveillance. Fifty-five were not eligible for this study because of
induction failure (n  6) or lack of a marker by RQ-PCR with a sensitivity
104 (n49).Thisproportionof ineligiblepatients is comparable to that in
the overall study.6,10 Of 221 eligible patients, 110 accepted surveillance BM
sampling.
Statistical Analysis
2orFisher’s exact testswereused toevaluate theassociationbetweenthe
frequency ofmain characteristics and that ofMRDpositivity duringmonitor-
ing. Disease-free survival (DFS) and cumulative incidence of relapse (CIR)
were the main end points for outcome analysis. DFS was defined as the time
fromdiagnosis to first treatment failure,whichwas defined as relapse, death in
remission, or development of second malignant neoplasm. Observation of
patients was censored at the time of last contact, when no events were ob-
served. The Kaplan-Meier method was used to estimate probabilities of DFS
with SEs calculated according to Greenwood’s formula and CIR (because no
competing eventswere observed). TheCox regression analysis was performed
on the cause-specific hazard of relapse to evaluate the MRD profile after
adjusting for risk group. Analyses were carried out by using SAS 9.2 (SAS
Institute, Cary, NC).
DNA Isolation
Mononuclear cells were isolated by Ficoll-Paque gradient centrif-
ugation, and DNA was extracted and purified by using the GentraPure-
geneDNAPurificationKit (Gentra Systems,Monza, Italy) according to the
manufacturer’s instructions.
Identification of PCR Targets and Design of
Allele-Specific Oligonucleotides
Genomic DNA samples obtained at diagnosis and at relapse were
screened for clonal immunoglobulin H/K chain, T-cell receptor gene rear-
rangements, and SIL-TAL by using published primer sets.17,22,23 Clonal im-
mune gene rearrangements were identified by heteroduplex analysis and
sequenced by using the BigDye Terminator Cycle Sequencing Kit with the
ABIPrism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA). After
sequencing, allele-specific oligonucleotides were designed for each PCR target
based on the sequence data of the junctional region by using Primer Express
software v3.0 (Applied Biosystems).
Evaluation and Interpretation of MRD RQ-PCR Results
The designed allele-specific oligonucleotides were then tested in combi-
nation with germ-line primers and TaqMan probes by RQ-PCR using the
7900HT Sequence Detection System (Applied Biosystems). PCR analysis was
then performed and results were interpreted according to the guidelines de-
veloped by the European Study Group on MRD Detection in ALL (Euro-
MRD) to reduce the risk of false-negative and false-positive results.24 Briefly,
three replicateswere performed forMRDanalysis for eachTP; 500 ng ofDNA
per 25 L was used for each reaction; six replicates of the polyclonal control
were used to define the background amplification. Although two informative
markers were mandatory for MRD stratification by study design in the
AIEOP-BFM ALL 2000 trial, our study included patients with a single infor-
mative marker.
Surveillance MRD results were categorized as MRD negative in the
absenceof specific amplificationor amplificationwithin three threshold cycles
of the background to exclude false-positive results; as MRD low positive if
positivity was less than 5 104 or below the achieved quantitative range (ie,
notquantifiable); or asMRDhighpositive if thepositivitywas5104, the
threshold used in the AIEOP-BFMALL 2000 study to defineHR-MRD levels
after induction and consolidation.
RESULTS
Study Population
The main features of the 110 study patients are summarized in
Table 1. The analysis found a strong association between higher PCR
MRD levels at the twoAIEOP-BFMALL2000protocol TPs (TP1, day
33; TP2, day78) and the frequency ofMRDpositivity at later TPs;
patients with favorable genetic features (hyperdiploidy or TEL-AML
positivity) and B-cell precursor immunophenotype were less likely
(althoughnot significantly) to haveMRDpositivity at later TPs. Table
2 depicts the outcome of treatment: at amedian follow-up time of 9.8
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Table 1. Main Characteristics of 110 Patients With Childhood ALL Who Underwent PCR-MRD Monitoring Performed During and After Treatment Completion
Characteristic
Total
PCR-MRD
P
Negative
Low Positive
( 5  104)
High Positive
( 5  104)
No. % No. % No. % No. %
Total No. of patients 110 81 73.6 23 20.9 6 5.5
Sex .74
Male 54 49.1 39 48.2 12 52.2 3 50.0
Female 56 50.9 42 51.8 11 47.8 3 50.0
Age (years) 1.0
1-9 93 84.6 68 84.0 20 87.0 5 83.3
10-17 17 15.4 13 16.0 3 13.0 1 16.7
WBC count (per microliter) .38
 100,000 103 93.6 77 95.1 21 91.3 5 83.3
 100,000 7 6.4 4 4.9 2 8.7 1 16.7
Phenotype .24
T-ALL 9 8.2 5 6.2 2 8.7 2 33.3
BCP-ALL 101 91.8 76 93.8 21 91.3 4 66.7
Hyperdiploidy or TEL/AML1 positive .10
Yes 50 48.5 41 53.2 7 35.0 2 33.3
No 53 51.5 36 46.8 13 65.0 4 66.7
Not known 7 4 3 0
Response to PDN 1.0
PGR 106 96.4 78 93.8 23 100.0 5 83.3
PPR 4 3.6 3 3.7 0 1 16.7
PCR-MRD level on day 33 .009
Negative 48 44.0 40 49.4 8 34.8 0
Low positive 42 38.5 32 39.5 9 39.1 1 20.0
High positive 19 17.5 9 11.1 6 26.1 4 80.0
Not known 1 0 0 1
PCR-MRD level on day 78  .001
Negative 87 79.1 73 90.1 14 60.9 0
Low positive 20 18.2 8 9.9 8 34.8 4 66.7
High positive 3 2.7 0 1 4.3 2 33.3
Final stratification by AIEOP-BFM ALL 2000 protocol .15
Standard risk 42 38.2 35 43.2 7 30.4 0
Intermediate risk 61 55.4 42 51.8 15 65.2 4 66.7
High risk 7 6.4 4 4.9 1 4.4 2 33.3
Abbreviations: AIEOP-BFM ALL 2000, International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia; ALL, acute
lymphoblastic leukemia; BCP-ALL, B-cell precursor ALL; MRD, minimal residual disease; PCR, polymerase chain reaction; PDN, prednisone; PGR, prednisone good
responder; PPR, prednisone poor responder; T-ALL, T-cell ALL.
Table 2. Treatment Outcome of 110 Patients With Childhood ALL, According to the Results of PCR-MRD Monitoring Performed After
Induction-Consolidation Treatment
Outcome
Total
PCR-MRD
Negative
Low Positive
( 5  104)
High Positive
( 5  104)
No. % No. % No. % No. %
Total No. of patients 110 81 23 6
First remission 87 79.1 72 88.9 14 60.9 1 16.7
Relapsed 23 20.9 9 11.1 9 39.1 5 83.3
Site
BM isolated 17 6 6 5
BM combined 3 1 2 0
Extramedullary 3 2 1 0
Abbreviations: ALL, acute lymphoblastic leukemia; BM, bone marrow; MRD, minimal residual disease; PCR, polymerase chain reaction.
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years, 23 patients (20.9%) had developed a relapse isolated in the BM
(n 17), in an extramedullary site (n 3), or in a combination of the
two (n  3), either during or after completion of treatment. All
relapses showed the same gene rearrangement already identified at
diagnosis. The remaining 87 patients (79.1%) were in first CR at the
time of last follow-up. The probability of 5-year DFS was 81.8% (SE,
3.7%), with a CIR of 18.2% (SE, 3.7%). Their probability of 5-year
DFS was not different from that of the whole AIEOP-BFM ALL
20006,10 cohortofpatients infirstCRafter induction IA(AppendixFig
A1, online only).
Association Between MRD Results and Outcome
A total of 588 samples were analyzed, with a median of five
samples per patient. The molecular markers analyzed are listed
in Appendix Table A1 (online only). Overall, of the 588 samples,
539 (91.7%) were classified as negative, 41 (7%) as MRD low
positive, and eight (1.4%) as MRD high positive based on at least
one marker.
Of the 110 patients included in this study, six (5.5%) had one or
moreMRDhigh-positive results during theobservation time, andfive
of them subsequently relapsed at 1, 3, 3, 8, and 12 months from the
first high-positive result (Table 2 andAppendix FigA2 [online only]).
Thus, the positive predictive value (ie, the probability of relapsing
given anMRD high-positive finding after day78) was 83%. A total
of 23 patients were classified as low positive at one or more TPs; of
those patients, nine relapsed at a median of 18 months after the
initial positive finding, with a positive predictive value of 39%; the
median follow-up after first positivity of the remaining 14 patients
in CR was 9.8 years. A total of 81 patients wereMRD negative at all
testedTPs; of them, nine relapsed, indicating that the probability of
remaining in remission, given that MRD never reached positivity
during postinduction treatment (ie, the negative predictive value)
was 89%.
The rate of relapsewas similar for patientswithT-lineage (twoof
nine patients) or B-lineage (21 of 101) ALL. Among patients with
B-lineage ALL, all four patients with high MRD positivity relapsed,
accounting for 20% of all relapses. Of interest, of three patients with
B-lineageALLwhodevelopedan isolated extramedullary relapse soon
after stopping therapy, one had a single low-positive result at an initial
TP and tested negative thereafter, and the other two always tested
MRD negative (Appendix Fig A2).
The 5-year CIR was 8.6% (SE, 3.1%) for the MRD-negative
patients, 34.8% (SE, 9.9%) for the patients who had at least one
low-positive result, and83.3%(SE, 15.2%) for thepatientswhohad at
least one high-positive result (Fig 1). Thus, detection ofMRDpositiv-
ity was significantly related to the risk of relapse (P .001).
We also evaluated,within the larger subgroupof 96 patientswith
B-lineage ALL without HR features, whether the MRD profile was
predictive of the risk of relapse after adjusting for risk group (SR v IR)
in a Cox model. Patients with at least one low-positive (hazard ratio,
4.3; 95% CI, 1.53 to 12.0; P  .006) or high-positive (hazard ratio,
21.2; 95%CI,4.9 to91.0;P .001)valuehada significantlyhigher risk
of relapse.
To assess the added value of short-term versus long-term
MRD monitoring, we separately analyzed patients who had MRD
positivity (n  18) or negativity (n  86) shortly after the
induction-consolidation phases (ie, within 4 months after day
78; six patients were not evaluated for early MRD). Of the 18
patients with early MRD positivity, one relapsed early (HR patient
108); 12 tested repeatedly positive at serial MRD measurements,
and five of them relapsed; five subsequently tested MRD negative,
but three of them eventually relapsed, too; thus the total number of
relapses in this subgroupwas nine (50%). Interestingly, one patient
with T-cell ALL (T-ALL) repeatedly tested positive up to the end of
treatment; nevertheless, he remained in CR for 12 years after the
diagnosis (IR patient 99).
Of the 86 patients who were found to be MRD negative in
the 4 months following the induction-consolidation phases, 77
(90%) remained negative thereafter at all the TPs tested, and
nine (10%) eventually relapsed; the remaining nine patients
instead showed MRD positivity at one (or more) following TPs,
and four of them relapsed. Of the six patients who lacked early
MRD follow-up, two showed subsequent MRD positivity, and
one of them relapsed.
DISCUSSION
The prognostic value of MRD in childhood ALL has been firmly
established by several groups worldwide. In particular, the use of
RQ-PCR MRD has been widely documented by the AIEOP-BFM
clinical trials as feasible and reproducible.6,10 The issue ofMRDmon-
itoring at later TPs has been considered since the early 1990s. In the
pioneering study by Van Dongen et al,5 any MRD positivity at any
single TP during first-line treatment was predictive of poor outcome.
However, because of the high predictive value of combined MRD
results at thefirst twoTPs andbecause of the rarity of positivity at later
TPs, systematicMRDmonitoring after induction-consolidation ther-
apywasconsidered tobenotcost-effective. In2003, theAustralianand
New Zealand Children’s Cancer Study Group reported the results of
MRD monitoring at 1 and 2 years from diagnosis, in which patients
with positive MRD underwent treatment intensification.25 The mi-
norityofpatientswith lateMRDpositivityhadapooroutcomedespite
0
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Time From Diagnosis (years)
1.0
0.8
0.6
0.4
0.2
1 2 3 4 5
 N pts N rel 5-yr Cum Inc Rel
Neg 81 9 8.6% (3.1)
Low Pos 23 9 34.8% (9.9)
Pos 6 5 83.3% (15.2)
Fig 1. Cumulative incidence of relapse (Cum Inc Rel) in 110 children with acute
lymphoblastic leukemia, according to the results of polymerase chain reaction
monitoring of minimal residual disease during postinduction treatment. Numbers
in parentheses represent SE. Neg, negative; Pos, positive.
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MRD-directed treatment intensification. Their data allowed the con-
clusion that systematic MRD monitoring at late TPs could not be
recommended.26 In our study, we explored the application of ex-
tended, prospective PCRMRDmonitoring beyond the two TPs used
for patient stratification in the AIEOP-BFM studies. The results are
strongly predictive of the individual patient’s outcome: indeed, pa-
tients with high-positive levels ( 5  104) had a high risk of
developing a BM relapse during treatment (five relapses in six pa-
tients). This compareswith a 39% relapse rate in patientswith a single
or repeated MRD low-positive result ( 5  104) and an 11%
relapse rate in patients with a negativeMRD profile.
These findings are in keeping with the results obtained by Raff
et al20 in the GMALL (German Multicenter Trial for Treatment of
NewlyDiagnosed Acute Lymphoblastic Leukemia in Adults) 06/99
trial and the GMALL 07/2003 trial in which conversion to MRD
positivity during the early postconsolidation phase in adult pa-
tients with SR-ALL was highly predictive of subsequent hemato-
logic relapse. Yet our data are only partially in keeping with the
recent experience of the German Multicenter Study Group for
Adult ALL, documenting that patients in molecular CR after con-
solidation had a significantly higher probability of both overall
survival and DFS compared with patients with evidence of molec-
ular relapse. However, in the adult setting, patients with molecular
relapse without transplantation in first CR had a median time to
cytologic relapse of 2.6 months fromMRD positivity and a proba-
bility of continuous complete remission of only 5%.27 In our
experience, the probability of continuous complete remission was
60% in patients (n  9) who tested positive only at later TPs and
50% in patients (n  18) who had a molecular positivity early
(within 4 months) after induction-consolidation therapy. Al-
though definitely better than the outcome in adult patients, the
outcomeof this last group is considered inadequate comparedwith
that of the general population of patients with childhood ALL.
They account for 16% (18 of 104) of the patients and can be
identified by a relatively low-cost MRD monitoring at a single
additional TP within 4 months after induction and consolidation
therapy. Monitoring appears to be indicated, especially in patients
who test MRD positive at day 78 via PCR: among 21 such
patients, 11 remained MRD positive, and five of them relapsed.
Early therapeutic interventions with alternative agents and/or with
allogeneic HSCT in first CR appears to be indicated. Otherwise,
systematic MRD monitoring in 86 patients who were MRD nega-
tive within 4 months after induction-consolidation therapy al-
lowed the identification of only nine patients with MRD positivity
later on, and four of them relapsed (three close to stopping therapy,
one at 7.5 years after diagnosis). It should also be noted that nine
relapses occurred in 77 patients (12%) in whomno positive signals
were detected.
The finding of persistence of MRD-positive results throughout
continuation chemotherapy, despite continuous CR in one patient, is
puzzling. This patient had IR T-ALL, with adequate initial response
(good response to steroid prephase) and lowMRD positivity at TP2.
Because (by study design) the attending physicians and the family
were blinded to the results of the MRD analysis at later TPs, this
patient did not receive any additional treatment intensification or
extension.MRDmeasurements after TP2 had never been done in the
cooperative AIEOP-BFM group outside this study. In patients with
T-ALL and comparable MRD levels in the AIEOP-BFM ALL 2000
study, the probability of remaining relapse-free was 74%.10 The pat-
tern of MRD in this patient might represent the tip of the iceberg if
MRD levels fluctuate around and below the threshold of detection; if
so, cure for ALL might not necessarily result from complete eradica-
tion of the disease. This hypothesis might also explain why patients
may occasionally test low positive throughout maintenance therapy
without developing relapse, as observed in our study, and it confirms
that the definition of molecular relapse remains quite intriguing.18,19
In this context, the risk of falseMRDpositivity should also be consid-
ered. This risk is higher for low levels of MRD, and for this reason we
applied the EuroMRD guidelines in a more conservative way, as ex-
plained in Patients and Methods. Theoretically, false MRD positivity
could also occur in the case of persistence of the preleukemic genetic
aberration28 or of the chromosomal lesion in a nonappropriated tar-
get cell.29Ourpatient 99was actuallymonitoredbyusing theSIL-TAL
genomic break point marker, in which a putative preleukemic origin
of the translocation cannot be ruled out.
Yet theunsolveddilemmaremainsonwhether available technol-
ogies are able to define premorphologic relapse at a time interval
which may become suitable for useful clinical intervention. It is
interesting to remember that, in the past, an attempt to herald
leukemia by the peripheral cell blood count did not result in any
therapeutic advantage for the children and was thus abandoned.30
In addition, it should be considered that systematic MRD moni-
toring implies a major investment of resources and an important
psychological burden on patients and families. These aspects de-
serve attention when drawing conclusions about the results of
protracted MRD monitoring.
In our opinion, our data suggest that additional MRD evalu-
ation within a few months after induction and consolidation ther-
apy may be clinically justified, particularly in patients who did not
reach MRD negativity, because it allows identification of a non-
negligible fraction of patients who have a high risk of relapse. This
is important in non-HR patients, in whom it is worth investigating
whether molecular slow responders may have an advantage from
an early intervention. In HR patients, this strategy may provide
useful information to define the timing of HSCT or to assess the
benefit of specific therapeutic interventions. Systematic monitor-
ing of MRD in patients who reach MRD negativity by the end of
induction-consolidation therapy appears to be not justified in
our experience.
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Appendix
Treatment Protocol
All patients were given 7 days of prophase therapy, including steroid therapy (prednisone) and one intrathecal dose ofmethotrexate
(MTX), followed by induction protocol IA and induction consolidation protocol IB; on day 8, patients were randomly assigned to
continue steroid treatment with either prednisone (60 mg/m2 per day) or dexamethasone (10 mg/m2 per day) until day 28 (the dose of
steroid [prednisone or dexamethasone] was tapered at the end of the time interval for full-dose assumption). Standard-risk patients
received four courses of high-dose MTX (2 g/m2; protocol M) and intermediate-risk patients received 5 g/m2; protocol M), oral
6-mercaptopurine, and intrathecal therapy. At the beginning of the reinduction phase, a second randomization was planned: for
standard-risk patients, protocol II versus reduced-intensity protocol III; for intermediate-risk patients, protocol II versus reduced-
intensity protocol III given twice; for high-risk patients, three blocks of non–cross-resistant drugs followed by protocol III given three
times versus protocol II given twice.Maintenance therapy consisted of 6-mercaptopurine once per day andMTXonce per week until 24
months fromdiagnosis. CNS-directed therapy consisted of intrathecalMTXduring each treatment phase including continuation unless
cranial radiotherapy (dosage by age) was given to the following patients: high-risk patients age 2 years or older, or those with non–high-
risk T-ALL and leukocyte count of more than 100,000/L at diagnosis, or those with CNS involvement.
Table A1. Molecular Markers
Patient Marker Quantitative Range Sensitive Range Present in the Relapse
1 VH3JH4 1  104 1  105 X
2 VH6JH5 5  104 1  105 X
3 VKIIKDE 5  104 1  105 X
4 VH1JH4 1  103 1  104 X
5 DH5JH5 1  103 1  105 X
6 VH3JH6 5  104 1  105 X
7 VH1JH6 1  104 1  105 Yes
8 VH1JH6 1  104 1  105 Yes
9 VH2JH6 1  103 1  105 X
10 VKIIKDE 1  103 1  105 Yes
11 VH1JH4 5  104 1  104 X
12 VH3JH5 1  103 1  104 X
13 DH4JH6 5  104 1  105 X
14 VD2DD3 1  104 1  104 X
15 VH4JH4 1  104 1  105 X
16 VH3JH1 5  104 1  104 X
17 VH6JH4 5  104 1  105 X
18° VH3JH6 ND† 1  104 Yes
19 VH4JH2 1  104 1  105 X
20 VKIKDE 1  104 1  105 X
21 VD2JD1 1  103 1  104 X
22 VH3JH6 5  104 1  104 X
23 VH3JH6 1  104 1  105 X
24 VH3JH4 1  104 1  105 X
25 VH3JH6 5  104 1  104 X
26 VH3JH5 1  104 1  105 X
27 DH6JH4 5  104 1  104 X
28 VH1JH5 1  104 1  105 X
29 VH3JH4 1  103 1  105 X
30 VD2DD3 1  104 1  104 X
31 VH4JH6 1  105 1  105 X
32 VH4JH5 1  104 1  105 X
33 DD2DD3 5  104 1  104 X
34 VH3JH6 5  104 1  105 X
35 VH3JH4 1  104 1  105 X
36 VH3JH4 1  104 1  104 X
37 VH6JH4 1  104 1  105 X
38 VH7JH6 1  103 1  104 X
39 VH3JH6 1  103 1  105 X
40 VH6JH6 5  104 1  104 X
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Table A1. Molecular Markers (continued)
Patient Marker Quantitative Range Sensitive Range Present in the Relapse
41 VH1JH4 1  104 1  105 X
42 VH1JH4 1  103 1  105 X
43 VKIIIKDE 1  104 1  105 Yes
44 VH3JH6 5  104 1  105 X
45 VH3JH4 1  104 1  105 X
46 VH2JH4 1  103 1  105 X
47 VH4JH4 1  104 1  105 Yes
48 VH1JH6 1  104 1  105 X
49 VH4JH6 1  104 1  104 X
50 VD1JD1 1  103 1  105 X
51 VH4JH6 1  104 1  105 X
52 VH3JH3 5  104 1  105 X
53 VH3JH3 1  104 1  105 X
54 VD2DD3 1  104 1  105 X
55 VH3JH6 1  104 1  105 X
56 VKIKDE 5  104 1  105 X
57 VD2DD3 1  103 1  105 X
58 VD2DD3 1  103 1  104 X
59 VH3JH4 1  104 1  104 X
60 VD2DD3 5  104 1  105 X
61 VB6.4JB1.5 5  104 1  104 X
62 VH3JH5 1  103 1  104 X
63 VH4JH4 1  103 1  105 Yes
64 VKIIKDE 1  103 1  104 X
65 VH4JH4 1  104 1  105 X
66 VH3JH4 5  104 1  105 X
67 VH3JH4 1  104 1  105 X
68 VD2DD3 1  103 1  104 Yes
69 VH3JH5 5  104 1  104 X
70 VH3JH5 1  103 1  104 X
71 VH2JH6 5  104 1  105 X
72 VH3JH4 1  104 1  105 Yes
73 VKIKDE 1  103 1  104 X
74 VH1JH6 1  104 1  105 X
75 VH3JH4 1  103 1  104 X
76 VH5JH6 5  104 1  105 X
77 VH1JH6 5  104 1  104 X
78 DH6JH6 1  105 1  105 X
79 VD2DD3 1  103 1  105 Yes
80 DH3JH6 5  104 1  104 Yes
81 DH6JH4 1  104 1  105 X
82 VD1JD1 5  104 1  105 X
83 DH4JH6 5  104 1  105 X
84 VH3JH6 1  104 1  105 X
85 VH3JH5 1  104 1  104 X
86 VH1JH6 1  104 1  105 X
87 DD2DD3 1  103 1  104 X
88 VH2JH6 1  103 1  104 Yes
89 VH1JH4 5  104 1  104 Yes
90 VKIIKDE 1  103 1  104 X
91 VH6JH5 5  104 1  104 Yes
92 VH3JH6 5  104 1  104 Yes
93 VD1JD1 1  103 1  105 X
94 VD2DD3 5  104 5  104 X
95 DH6JH4 1  103 1  104 X
96 VH1JH2 5  104 1  105 X
97 VD2DD3 5  104 1  105 X
98 VD2DD3 5  104 1  104 X
99 SILTAL 5  104 1  105 X
(continued on following page)
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Table A1. Molecular Markers (continued)
Patient Marker Quantitative Range Sensitive Range Present in the Relapse
100 VH3JH6 1  104 1  105 Yes
101 VH1JH4 1  103 1  104 Yes
102 VD2DD3 1  104 1  105 X
103 VH3JH4 1  103 1  104 Yes
104 VH2JH4 5  104 5  104 Yes‡
105 VH3JH3 5  104 1  105 X
106 VD2DD3 1  104 1  105 X
107 VG8JG1.3 1  104 1  105 Yes
108 VH6JH4 1  104 1  104 Yes
109 VD1JD1 1  104 1  104 Yes
110 DH7 1  103 1  105 Yes
Abbreviations: ND, not determined; X, not tested, the patient did not relapse.
Low positivity in the bone marrow.
†It was not possible to determine the QR for the patient on 7700. The marker was acquired on 7700 Sequence Detection System (Applied Biosystems); we could
not re-analyze the data according to the guidelines24 to give the quantitative range so we define only the sensitive range.
‡Patient 104 partially modified the rearrangement; the MRD primer was designed in the conserved N-region between the DH and JH.
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Fig A1. Disease-free survival of the 110 patients selected for this study compared with that of the total study population of the International Collaborative Treatment
Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000) who reached complete remission by the end of phase IA. Our total
study population had an outcome that was comparable to that of the overall AIEOP-BFM ALL 2000 study population. Numbers in parentheses represent SE. No Anal,
no analysis; pts, patients; rel, relapse.
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Fig A2. Results of the postinduction monitoring of bone marrow minimal residual disease (MRD) in individual study patients. bm, bone marrow; em, extramedullary;
HR, high risk; IR, intermediate risk; SR, standard risk. (*) 2 bm samples. (†) T lineage; all other cases were of B lineage.
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